Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PPP5C | P53041 | 1/20 | 0.42 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32690600 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL336246 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL4968628 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL5525143 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL18923859 | 1.00 | KDM4E (0.42) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL24453673 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL22300107 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL20963065 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL22300602 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC | |
| SCHEMBL22300609 | 0.97 | KDM4E (0.40) | KDM4EGMNNPPM1BLMNAPPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021085-A1 | CYCLOALKYL CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-119569706-A | Therapeutic compounds | 希四克斯探索有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-112996785-B | Therapeutic compounds | 希四克斯探索有限公司 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024059659-A1 | CYCLOALKYL CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024059661-A1 | N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11021455-B2 | Brominated furanone derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-06-01 | — | — | US | disclosed |
| US-20190345126-A1 | NOVEL BROMINATED FURANONE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2019-11-14 | — | — | US | disclosed |
| WO-2019183577-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| US-5886024-A | ENZYME INHIBITOR FOR TREATING ARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA | BAYER CORPORATION (US) | 1999-03-23 | — | — | US | disclosed |
| US-5874473-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS | BAYER CORPORATION (US) | 1999-02-23 | — | — | US | disclosed |
| US-5861428-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, INFLAMMATION, OSTEOPENIAS, TEMPERO | BAYER CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5861427-A | ALLEVIATION OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, PROTEINURIA, ANEURYSMAL AORTIC DISEASE, DYSTROPHOBIC EPIDERMOLYSIS BULLOSA, CONDITIONS LEADING TO INFLAMMATORY | BAYER HEALTHCARE LLC | 1999-01-19 | — | — | US | disclosed |
| US-5859047-A | ANTIARTHRITIC AGENTS, NERVOUS SYSTEM DISORDERS | BAYER CORPORATION (US) | 1999-01-12 | — | — | US | disclosed |
| US-5854277-A | Thiophenebutanoic acid derivatives as matrix metalloprotease inhibitors | BAYER CORPORATION (US) | 1998-12-29 | — | — | US | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4206137-A | Thioalkanoylalkanoic acid compounds | E. R. SQUIBB & SONS, INC. (US) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | KDM4E 3433/4885GMNN 3401/4885PPM1B 717/4885 |
| US-11021455-B2 | Brominated furanone derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient | TAS2R20, BLVRB, FDPS | KDM4E 385/4885GMNN 3407/4885PPM1B 270/4885 |
| US-20260021085-A1 | CYCLOALKYL CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF | GYS2, GYS1, PYGL | KDM4E 3922/4885GMNN 2342/4885PPM1B 264/4885 |
| US-20190345126-A1 | NOVEL BROMINATED FURANONE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | TAS2R20, BLVRB, NOTUM | KDM4E 488/4885GMNN 3231/4885PPM1B 284/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | KDM4E 3179/4885GMNN 3442/4885PPM1B 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.